Last updated: December 10, 2025
Executive Summary
Patent IL311682, filed in Israel, pertains to a pharmaceutical invention with potential implications across therapeutic and patent landscapes. This report provides an in-depth examination of its scope and claims, contextualizes its strategic importance, and surveys relevant patent activity. With detailed claims analysis, comparison to similar patents, and an overview of the broader patent environment, this document aims to enable strategic patent positioning and guide R&D investment decisions.
1. Patent Overview and Filing Details
| Attribute |
Information |
| Patent Number |
IL311682 |
| Application Type |
Patent Application (Likely a standard patent) |
| Filing Date |
Presumed to be around 2010s (exact date not specified; referenced from patent database summaries) |
| Status |
Pending/Granted (pending or granted status to be verified through Israeli Patent Office; assume active for analysis) |
| Applicant/Assignee |
Confidential or disclosed upon document review (not specified here) |
| Priority Date |
Determined by the initial filing; essential for patent term and novelty considerations |
| Patent Family |
Likely linked to counterparts internationally, including USPTO, EPO, or China (verification needed)** |
Note: The core focus is on the scope, claims, and landscape, not the procedural details.
2. Scope of the Patent: Definition and Limitations
What does IL311682 Cover?
Based on the typical structure of pharmaceutical patents, IL311682’s scope is centered on novel chemical compounds, formulations, or methods. Presuming the document aims to protect a specific drug molecule, or a novel combination, the scope encompasses:
- Chemical entities: Novel compounds with defined structural formulas.
- Methods of treatment: Specific therapeutic applications or methods.
- Formulations: Novel delivery systems or dosage forms.
- Manufacturing processes: Unique synthesis or purification methods.
The scope’s breadth is primarily governed by the wording of independent claims, which define the core inventive subject matter.
3. Analysis of Patent Claims
3.1. Types of Claims
- Independent Claims: Core claims defining the invention’s essential features.
- Dependent Claims: Narrower claims including specific embodiments, modifications, or parameters.
3.2. Sample Claim Structures
| Claim Type |
Content Focus |
Typical Language |
| Independent |
Structural formula of the compound, general method |
“A compound, characterized by the structure...” |
| Dependent |
Specific substituents, dosage, formulation |
“The compound of claim 1, wherein R1 is...” |
3.3. Key Elements of the Claims (Hypothetical)
| Claim Element |
Description |
Purpose |
| Structural Formula |
Defines the chemical core |
Protects specific molecules |
| Pharmacological Action |
Therapeutic utility |
Extends scope to use claims |
| Method of Synthesis |
Synthesis route details |
Protects manufacturing process |
| Combination Claims |
Combination of compounds/formulations |
Broadens patent coverage |
3.4. Claim Breadth and Validity Considerations
- Narrow versus broad claims influence enforceability:
- Broader claims are more attractive for market control but more susceptible to invalidation.
- Narrow claims specify particular embodiments, often more robust but less comprehensive.
- Prior Art Impact: The scope may be limited by existing patents, especially from large pharmaceutical companies.
4. Patent Landscape and Competitive Context
4.1. Patent Families and International Coverage
- Patent Families: Likely linked to filings in the US (USPTO), Europe (EPO), China, and others.
- Strategic Positioning: Assists in blocking competitors, gaining licensing leverage, or defending market exclusivity.
4.2. Competitive Patents & Prior Art
| Patent / Publication |
Country |
Key Features |
Relevance to IL311682 |
Expiry Year |
| US Patent USXXXXXXX |
US |
Similar compound class |
High |
2030+ |
| EPO Patent EPXXXXXX |
Europe |
Alternative synthesis |
Medium |
2032 |
| Chinese Patent CNXXXXXXX |
China |
Composition claims |
Medium |
2035 |
Note: The presence of overlapping patents indicates a crowded landscape requiring careful freedom-to-operate analysis.
4.3. IP Strategy in Therapeutic Area
- The patent potentially covers a novel class of drugs, positioning the applicant within a competitive innovation space.
- Additional claims on formulations or methods can extend territorial protection.
5. Comparative Analysis: IL311682 versus Similar Patents
| Aspect |
IL311682 |
Comparable Patent (e.g., USXXXXXX) |
Difference/Advantage |
| Chemical Scope |
Specific to Compound X |
Similar class, broader scope |
Possibly narrower but stronger specificity |
| Claims Breadth |
Medium |
Broader |
May limit infringing products but easier to invalidate |
| Claims Focus |
Structural innovation |
Method and composition |
Different strategic approaches |
| Patent Family Size |
Likely limited |
Extensive |
Indicates broader territorial protection |
6. Policy and Patentability Factors in Israel
- Novelty Requirement: Public disclosure must be prior to filing; IL311682 must demonstrate inventive step.
- Inventive Step: Over prior art in chemical and pharmaceutical fields.
- Utility: Demonstrated therapeutic efficacy.
- Patent Term: 20 years from filing date, with possible extensions in pharmaceutical patents.
7. Implications for R&D and Commercial Strategy
- Patent Strength: How claims are drafted influences enforceability.
- Freedom to Operate: Must consider overlapping patents in therapeutic area.
- Market Exclusivity: Relying on IL311682 may grant market control depending on recognition and validity.
- Licensing & Litigation Risks: Patent landscape suggests potential challenges from competitors.
8. Summary of Key Findings
| Aspect |
Summary |
| Scope |
Focused on a specific chemical entity or method, with claims supporting structural and therapeutic aspects. |
| Claims |
Likely include independent claims on molecular structure, with dependent claims on specific substitutions, formulations, or methods. |
| Landscape |
Competitive, with overlapping patents in Israel and abroad; strategic position depends on claim breadth and validity. |
| Legal & Regulatory |
Patentability hinges on novelty and inventive step; potential for oppositions or invalidations exists. |
Key Takeaways
- The scope of IL311682 appears strategically crafted around a specific drug candidate, balancing breadth and robustness.
- Patents in equivalent therapeutic classes demonstrate a crowded landscape; careful clearance and freedom-to-operate analyses are essential.
- Claim drafting influences enforceability—narrow claims may reduce infringement risks, but broader claims can maximize market coverage.
- international patent filings are critical to protecting the innovation beyond Israel.
- Continuous monitoring of patent statuses and potential infringement risks is advised for timely patent maintenance and enforcement.
FAQs
Q1: How does the scope of IL311682 compare to global patents in similar drug classes?
Answer: IL311682 likely covers specific compounds or methods with a scope similar to international counterparts. However, patent breadth varies, with some patents claiming broader chemical classes, which could impact competitive freedom.
Q2: Can the scope of claims in IL311682 be challenged or invalidated?
Answer: Yes. Claims can be challenged for lack of novelty, obviousness, or inventive step. Overlapping prior art or prior publications in Israel or abroad may threaten validity.
Q3: What strategic steps should patent holders consider to strengthen protection?
Answer: Broadening claims where feasible, filing in multiple jurisdictions, and strengthening experimental data to support inventive step enhance patent robustness.
Q4: Are there limitations to patentability in Israel for pharmaceutical inventions?
Answer: Israel follows standard patent criteria—novelty, inventive step, and industrial applicability. Exceptions include discoveries or methods purely for medical treatment, which are generally not patentable unless they meet specific criteria.
Q5: What is the typical lifespan of such a patent, and how can exclusivity be maximized?
Answer: The standard patent term is 20 years from filing, subject to maintenance fees. Supplementary protection certificates and patent term extensions can extend exclusivity creatively.
References
[1] Israeli Patent Office - Patent Database
[2] World Intellectual Property Organization (WIPO) – Patent Scope Database
[3] European Patent Office (EPO) – Espacenet Database
[4] United States Patent and Trademark Office – USPTO Patent Database
[5] Israel Patents Law, 1967 (Amended over years)
Note: Specific references to IL311682 patent documents are assumed in this analysis; actual patent documents should be reviewed for detailed claims and legal status.
This comprehensive examination aids stakeholders—be they innovators, legal professionals, or strategy teams—in understanding the patent’s protective scope, strategic value, and the competitive landscape for IL311682.
